Gerresheimer launches Open Innovation Program for the development of home therapy solutions
"The idea of allowing patients to continue treatment at home whenever the form of therapy allows is invaluable. We strongly believe that access to healthcare should be as convenient and easy as possible, especially for patients who are in an already challenging situation, for example during or after cancer therapy," says Maike Wolf, Head of Innovation at Gerresheimer.
Innovative solutions for drug delivery
Gerresheimer aims to improve the safety, efficiency and effectiveness of home therapy with its innovative containment and drug delivery systems for the delivery of liquid medications. In addition, the company is also working on the integration of digital technologies and remote monitoring capabilities to provide patients with seamless care and support.
To date, many patients with a wide variety of indications have to endure long and stressful infusions in a hospital setting to treat their condition. How much easier would it be if patients could receive treatment at home? The on-body drug delivery device Gx SensAir® makes life easier for these patients, as they can take care of themselves over a longer period of time and - depending on the indication - only need to visit the doctor or hospital for check-ups. Gx SensAir® is an innovative product platform for the delivery of large-volume and highly viscous biologics.
Open innovation program for sustainable and digital healthcare
By participating in the open innovation program with ekipa, Gerresheimer aims to help develop new therapy solutions across the healthcare value chain that meet the needs of many patient groups. Ekipa's HealthTech Innovation Program calls for the development of new approaches or the application of existing solutions to jointly build sustainable and digital healthcare.
Learn more about the Open Innovation Program
Contact Press
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 211 6181-246
marion.stolzenwald@gerresheimer.com
Jutta Lorberg
Head of Corporate Communication
T +49 152 900 345 46
jutta.lorberg@gerresheimer.com
About Gerresheimer
Gerresheimer is the innovative system and solution provider and global partner for the pharma and biotech industry. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health and cosmetics industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, dropper bottles, other bottles and more. Gerresheimer ensures the safe delivery and administration of drugs to the patient. With 36 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for the regional markets. With over 11,000 employees, the company generated revenues of around €1.82bn in 2022. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com
